1. Mertin S, McDowall SG and Harley VR (1999) The DNA-binding specificity of SOX9 and other SOX proteins. Nucleic Acids Res 27:1359-64. doi: 10.1093/nar/27.5.1359
2. Jo A, Denduluri S, Zhang B, Wang Z, Yin L, Yan Z, Kang R, Shi LL, Mok J, Lee MJ and Haydon RC (2014) The versatile functions of Sox9 in development, stem cells, and human diseases. Genes Dis 1:149-161. doi: 10.1016/j.gendis.2014.09.004
3. Grimm D, Bauer J, Wise P, Kruger M, Simonsen U, Wehland M, Infanger M and Corydon TJ (2020) The role of SOX family members in solid tumours and metastasis. Semin Cancer Biol 67:122-153. doi: 10.1016/j.semcancer.2019.03.004
4. Jana S, Madhu Krishna B, Singhal J, Horne D, Awasthi S, Salgia R and Singhal SS (2020) SOX9: The master regulator of cell fate in breast cancer. Biochem Pharmacol 174:113789. doi: 10.1016/j.bcp.2019.113789
5. Ma Y, Shepherd J, Zhao D, Bollu LR, Tahaney WM, Hill J, Zhang Y, Mazumdar A and Brown PH (2020) SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis. Mol Cancer Res 18:1825-1838. doi: 10.1158/1541-7786.MCR-19-0311
6. Aguilar-Medina M, Avendano-Felix M, Lizarraga-Verdugo E, Bermudez M, Romero-Quintana JG, Ramos-Payan R, Ruiz-Garcia E and Lopez-Camarillo C (2019) SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer. J Oncol 2019:6754040. doi: 10.1155/2019/6754040
7. Carrasco-Garcia E, Alvarez-Satta M, Garcia-Puga M, Ribeiro ML, Arevalo S, Arauzo-Bravo M and Matheu A (2019) Therapeutic relevance of SOX9 stem cell factor in gastric cancer. Expert Opin Ther Targets 23:143-152. doi: 10.1080/14728222.2019.1559826
8. Richtig G, Aigelsreiter A, Schwarzenbacher D, Ress AL, Adiprasito JB, Stiegelbauer V, Hoefler G, Schauer S, Kiesslich T, Kornprat P, Winder T, Eisner F, Gerger A, Stoeger H, Stauber R, Lackner C and Pichler M (2017) SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS One 12:e0187814. doi: 10.1371/journal.pone.0187814
9. Muller M, Fazi F and Ciaudo C (2019) Argonaute Proteins: From Structure to Function in Development and Pathological Cell Fate Determination. Front Cell Dev Biol 7:360. doi: 10.3389/fcell.2019.00360
10. Niaz S (2018) The AGO proteins: an overview. Biol Chem 399:525-547. doi: 10.1515/hsz-2017-0329
11. Xu K, Lin J, Zandi R, Roth JA and Ji L (2016) MicroRNA-mediated target mRNA cleavage and 3'-uridylation in human cells. Sci Rep 6:30242. doi: 10.1038/srep30242
12. Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20:515-24. doi: 10.1101/gad.1399806
13. Ricci EP, Limousin T, Soto-Rifo R, Rubilar PS, Decimo D and Ohlmann T (2013) miRNA repression of translation in vitro takes place during 43S ribosomal scanning. Nucleic Acids Res 41:586-98. doi: 10.1093/nar/gks1076
14. O'Brien J, Hayder H, Zayed Y and Peng C (2018) Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne) 9:402. doi: 10.3389/fendo.2018.00402
15. Jo MH, Shin S, Jung SR, Kim E, Song JJ and Hohng S (2015) Human Argonaute 2 Has Diverse Reaction Pathways on Target RNAs. Mol Cell 59:117-24. doi: 10.1016/j.molcel.2015.04.027
16. Peter ME (2010) Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 29:2161-4. doi: 10.1038/onc.2010.59
17. Lu TX and Rothenberg ME (2018) MicroRNA. J Allergy Clin Immunol 141:1202-1207. doi: 10.1016/j.jaci.2017.08.034
18. Weber CE, Luo C, Hotz-Wagenblatt A, Gardyan A, Kordass T, Holland-Letz T, Osen W and Eichmuller SB (2016) miR-339-3p Is a Tumor Suppressor in Melanoma. Cancer Res 76:3562-71. doi: 10.1158/0008-5472.CAN-15-2932
19. Valihrach L, Androvic P and Kubista M (2020) Circulating miRNA analysis for cancer diagnostics and therapy. Mol Aspects Med 72:100825. doi: 10.1016/j.mam.2019.10.002
20. Sabit H, Cevik E, Tombuloglu H, Abdel-Ghany S, Tombuloglu G and Esteller M (2021) Triple negative breast cancer in the era of miRNA. Crit Rev Oncol Hematol 157:103196. doi: 10.1016/j.critrevonc.2020.103196
21. Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, Aldahmash A and Alajez NM (2017) Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis 8:e3045. doi: 10.1038/cddis.2017.440
22. Kashyap D, Tuli HS, Garg VK, Goel N and Bishayee A (2018) Oncogenic and Tumor-Suppressive Roles of MicroRNAs with Special Reference to Apoptosis: Molecular Mechanisms and Therapeutic Potential. Mol Diagn Ther 22:179-201. doi: 10.1007/s40291-018-0316-1
23. Wang W and Luo YP (2015) MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B 16:18-31. doi: 10.1631/jzus.B1400184
24. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP and Tamayo P (2015) The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 1:417-425. doi: 10.1016/j.cels.2015.12.004
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-50. doi: 10.1073/pnas.0506580102
26. Sarver AL, Sarver AE, Yuan C and Subramanian S (2018) OMCD: OncomiR Cancer Database. BMC Cancer 18:1223. doi: 10.1186/s12885-018-5085-z
27. Liu F, Liu Y, Shen J, Zhang G and Han J (2016) MicroRNA-224 inhibits proliferation and migration of breast cancer cells by down-regulating Fizzled 5 expression. Oncotarget 7:49130-49142. doi: 10.18632/oncotarget.9734
28. Vejnar CE, Blum M and Zdobnov EM (2013) miRmap web: Comprehensive microRNA target prediction online. Nucleic Acids Res 41:W165-8. doi: 10.1093/nar/gkt430
29. Tahiri A, Leivonen SK, Luders T, Steinfeld I, Ragle Aure M, Geisler J, Makela R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Borresen-Dale AL, Perala M, Bukholm IR and Kristensen VN (2014) Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 35:76-85. doi: 10.1093/carcin/bgt333
30. Zhang J, Ma Y, Wang S, Chen F and Gu Y (2015) C/EBPalpha inhibits proliferation of breast cancer cells via a novel pathway of miR-134/CREB. Int J Clin Exp Pathol 8:14472-8.
31. Vega FM and Ridley AJ (2018) The RhoB small GTPase in physiology and disease. Small GTPases 9:384-393. doi: 10.1080/21541248.2016.1253528
32. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J and Pommier Y (2012) CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 72:3499-511. doi: 10.1158/0008-5472.CAN-12-1370
33. Oishi Y, Manabe I, Tobe K, Tsushima K, Shindo T, Fujiu K, Nishimura G, Maemura K, Yamauchi T, Kubota N, Suzuki R, Kitamura T, Akira S, Kadowaki T and Nagai R (2005) Kruppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab 1:27-39. doi: 10.1016/j.cmet.2004.11.005
34. Lee JE and Ge K (2014) Transcriptional and epigenetic regulation of PPARgamma expression during adipogenesis. Cell Biosci 4:29. doi: 10.1186/2045-3701-4-29
35. Panza A, Pazienza V, Ripoli M, Benegiamo G, Gentile A, Valvano MR, Augello B, Merla G, Prattichizzo C, Tavano F, Ranieri E, di Sebastiano P, Vinciguerra M, Andriulli A, Mazzoccoli G and Piepoli A (2013) Interplay between SOX9, beta-catenin and PPARgamma activation in colorectal cancer. Biochim Biophys Acta 1833:1853-65. doi: 10.1016/j.bbamcr.2013.04.004
36. Zhao M, Ji H, Fu Q, Cheng Q, Zhang Y and Yang Y (2021) MicroRNA-134-3p inhibits ovarian cancer progression by targeting flap structure-specific endonuclease 1 in vitro. Oncol Rep 45:119-128. doi: 10.3892/or.2020.7844
37. Qin Q, Wei F, Zhang J and Li B (2017) miR-134 suppresses the migration and invasion of nonsmall cell lung cancer by targeting ITGB1. Oncol Rep 37:823-830. doi: 10.3892/or.2017.5350
38. Pan JY, Zhang F, Sun CC, Li SJ, Li G, Gong FY, Bo T, He J, Hua RX, Hu WD, Yuan ZP, Wang X, He QQ and Li DJ (2017) miR-134: A Human Cancer Suppressor? Mol Ther Nucleic Acids 6:140-149. doi: 10.1016/j.omtn.2016.11.003
39. Xu R, Feng F, Yu X, Liu Z and Lao L (2018) LncRNA SNHG4 promotes tumour growth by sponging miR-224-3p and predicts poor survival and recurrence in human osteosarcoma. Cell Prolif 51:e12515. doi: 10.1111/cpr.12515
40. Wang G, Liu L, Zhang J, Huang C, Chen Y, Bai W, Wang Y, Zhao K and Li S (2020) LncRNA HCG11 Suppresses Cell Proliferation and Promotes Apoptosis via Sponging miR-224-3p in Non-Small-Cell Lung Cancer Cells. Onco Targets Ther 13:6553-6563. doi: 10.2147/OTT.S244181